Stable Angina

The overall prevalence of stable angina in the US is estimated at app. 4% of the adult population with 500,000 new cases of angina occurring annually.

Stable angina is characterized by recurrent episodes of reversible cardiac oxygen demand/supply mismatch typically resulting in pain or heaviness in the anterior chest and may be accompanied by fatigue resulting in poor quality of life.

Although cardiac ischemia is a metabolic disorder disrupting cellular energetics, there are currently no approved pharmacological therapies in the U.S. which directly address this by targeting cardiomyocyte metabolism. Pharmacological treatment of angina has traditionally focused on manipulating hemodynamics to reduce cardiac oxygen demand by lowering blood pressure, cardiac contractility, and/or heart rate using beta blockers, calcium channel antagonists, and nitrates frequently in combination. However, when titrated to effect, these agents often reach a plateau of hemodynamic suppression, where adding further dose increments or therapies with a similar hemodynamic mechanism of action confers little additive symptomatic benefit, while adverse effects increase, which may limit tolerability and prevent adequate symptom relief.

Our Phase 2 trial is evaluating the safety and anti-ischemic effects of ninerafaxstat administered for 8-weeks in patients with stable angina and chronic coronary syndrome.

References: Tsao et al., Circulation 2023 and NIH website.